- Home
- SKYH vs BBIO Comparison
SKYH vs BBIO Comparison
Compare SKYH & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYH | BBIO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 14.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SKYH | BBIO |
|---|---|---|
| Price | $8.94 | $76.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 21 |
| Target Price | $13.83 | ★ $76.24 |
| AVG Volume (30 Days) | 125.9K | ★ 2.0M |
| Earning Date | 11-12-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $24,125,000.00 | ★ $353,780,000.00 |
| Revenue This Year | $95.79 | $128.44 |
| Revenue Next Year | $69.76 | $76.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 95.23 | 62.46 |
| 52 Week Low | $8.22 | $26.55 |
| 52 Week High | $14.20 | $78.44 |
Technical Indicators
Market Signals| Indicator | SKYH | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 64.64 |
| Support Level | $8.49 | $73.48 |
| Resistance Level | $10.07 | $78.44 |
| Average True Range (ATR) | 0.33 | 2.36 |
| MACD | -0.07 | -0.18 |
| Stochastic Oscillator | 28.48 | 72.81 |
Price Performance
Historical ComparisonAbout SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.